Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
Financial Results:
Capri Global Capital Ltd reported Revenues for Q3FY25 of ₹821.00 Crores up from ₹605.00 Crore year on year, a rise of 35.7%.
Total Expenses for Q3FY25 of ₹651.00 Crores up from ₹516.00 Crores year on year, a rise of 26.16%.
Consolidated Net Profit of ₹128.00 Crores up 88.24% from ₹68.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹1.55, up 89.02% from ₹0.82 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
